S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.58 (+1.38%)
MSFT   317.63 (+0.60%)
META   304.83 (+1.54%)
GOOGL   132.88 (+1.54%)
AMZN   128.45 (+1.05%)
TSLA   248.86 (-0.54%)
NVDA   448.68 (+3.15%)
NIO   8.75 (-3.21%)
BABA   86.11 (-0.73%)
AMD   102.32 (-0.49%)
T   14.91 (-0.73%)
F   12.37 (-0.40%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.15 (-1.27%)
DIS   81.16 (+0.14%)
AMC   8.01 (+0.25%)
PFE   33.21 (+0.12%)
PYPL   59.14 (+1.16%)
NFLX   380.57 (+0.79%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.58 (+1.38%)
MSFT   317.63 (+0.60%)
META   304.83 (+1.54%)
GOOGL   132.88 (+1.54%)
AMZN   128.45 (+1.05%)
TSLA   248.86 (-0.54%)
NVDA   448.68 (+3.15%)
NIO   8.75 (-3.21%)
BABA   86.11 (-0.73%)
AMD   102.32 (-0.49%)
T   14.91 (-0.73%)
F   12.37 (-0.40%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.15 (-1.27%)
DIS   81.16 (+0.14%)
AMC   8.01 (+0.25%)
PFE   33.21 (+0.12%)
PYPL   59.14 (+1.16%)
NFLX   380.57 (+0.79%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.58 (+1.38%)
MSFT   317.63 (+0.60%)
META   304.83 (+1.54%)
GOOGL   132.88 (+1.54%)
AMZN   128.45 (+1.05%)
TSLA   248.86 (-0.54%)
NVDA   448.68 (+3.15%)
NIO   8.75 (-3.21%)
BABA   86.11 (-0.73%)
AMD   102.32 (-0.49%)
T   14.91 (-0.73%)
F   12.37 (-0.40%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.15 (-1.27%)
DIS   81.16 (+0.14%)
AMC   8.01 (+0.25%)
PFE   33.21 (+0.12%)
PYPL   59.14 (+1.16%)
NFLX   380.57 (+0.79%)
S&P 500   4,284.19 (-0.09%)
DOW   33,404.64 (-0.31%)
QQQ   360.14 (+0.52%)
AAPL   173.58 (+1.38%)
MSFT   317.63 (+0.60%)
META   304.83 (+1.54%)
GOOGL   132.88 (+1.54%)
AMZN   128.45 (+1.05%)
TSLA   248.86 (-0.54%)
NVDA   448.68 (+3.15%)
NIO   8.75 (-3.21%)
BABA   86.11 (-0.73%)
AMD   102.32 (-0.49%)
T   14.91 (-0.73%)
F   12.37 (-0.40%)
MU   67.88 (-0.22%)
CGC   0.79 (+0.77%)
GE   109.15 (-1.27%)
DIS   81.16 (+0.14%)
AMC   8.01 (+0.25%)
PFE   33.21 (+0.12%)
PYPL   59.14 (+1.16%)
NFLX   380.57 (+0.79%)
LON:HIK

Hikma Pharmaceuticals (HIK) Share Forecast, Price & News

GBX 2,053
-35.00 (-1.68%)
(As of 03:21 PM ET)
Compare
Today's Range
2,052
▼
2,093
50-Day Range
2,040.87
▼
2,205
52-Week Range
1,174.50
▼
2,222
Volume
311,955 shs
Average Volume
427,955 shs
Market Capitalization
£4.54 billion
P/E Ratio
3,801.85
Dividend Yield
2.44%
Price Target
GBX 1,939.17
ProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlinesSustainability

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
6.0% Downside
GBX 1,939.17 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
-0.21mentions of Hikma Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

See Top Rated MarketRank™ Stocks Here

HIK stock logo

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.

HIK Price History

HIK Stock News Headlines

October 2, 2023 | markets.businessinsider.com
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
September 28, 2023 | msn.com
Generic drugs still out of reach despite effort to ensure access
October 2, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 27, 2023 | msn.com
FTSE 100 sinks into the red despite gains for energy stocks
September 25, 2023 | msn.com
Popular Children’s Antibiotic Liquid Amoxicillin Still In Shortage—Here Are Alternatives And What To Know
September 7, 2023 | marketwatch.com
Arecor Therapeutics Partner Hikma Advances on Review of AT307 in US
September 6, 2023 | tmcnet.com
Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
August 31, 2023 | foxnews.com
Generic versions of Vyvanse released to address ADHD medicine shortage in US
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
August 31, 2023 | msn.com
M&S to make FTSE 100 comeback
August 30, 2023 | ft.com
Marks and Spencer to return to FTSE 100 after 4-year absence
August 30, 2023 | finance.yahoo.com
Marks & Spencer Makes a Return to the FTSE 100 as Hiscox Loses Out in Reshuffle
August 25, 2023 | finance.yahoo.com
Inotropic Agents Global Market Report 2023
August 24, 2023 | uk.finance.yahoo.com
Generic Injectables Global Market Report 2023
August 23, 2023 | msn.com
Resurgent M&S set for FTSE 100 return but builder Persimmon heads for the exit
August 23, 2023 | msn.com
Dechra Pharmaceuticals set for promotion to FTSE 100 alongside M&S
August 23, 2023 | yahoo.com
FTSE 100 Live: London top flight seen higher ahead of PMI reading, US bank downgrades, Klarna sales boom
August 22, 2023 | msn.com
M&S set for FTSE 100 return but builder Persimmon heading for exit
August 22, 2023 | benzinga.com
Prefilled Syringes Market Size & Share to Surpass $10.59 Billion by 2030 | Vantage Market Research
August 22, 2023 | msn.com
M&S set for promotion back into Ftse-100 as it stages recovery
August 3, 2023 | msn.com
Hikma reports strong H1 performance, raises generics drugs guidance
August 3, 2023 | finance.yahoo.com
TAKING ON THE OPIOID OVERDOSE EPIDEMIC IN NEW JERSEY
August 3, 2023 | msn.com
UK drugmaker Hikma raises annual outlook for generics arm
August 3, 2023 | marketwatch.com
Hikma Pharmaceutical 1H EPS 59.0c
August 3, 2023 | nasdaq.com
Hikma Pharma H1 Profit Down, Revenues Up; Lifts FY23 Forecast For Generics
July 27, 2023 | finance.yahoo.com
Octave Bioscience Closes $30M Extension to Series B Funding
July 25, 2023 | finance.yahoo.com
Inhalation Anesthesia Global Market Report 2023: Technological Advancements Driving Strong Growth in the Industry
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Ex-Dividend for 9/15 Dividend
8/10/2023
Dividend Payable
9/15/2023
Today
10/02/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:HIK
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
+44-20-73992760
Fax
N/A
Employees
8,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,939.17
High Stock Price Forecast
GBX 2,125
Low Stock Price Forecast
GBX 1,740
Forecasted Upside/Downside
-7.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.54
Trailing P/E Ratio
3,866.67
Forward P/E Ratio
12.85
P/E Growth
1.93
Net Income
£146 million
Net Margins
5.35%
Pretax Margin
N/A
Return on Equity
6.74%
Return on Assets
8.06%

Debt

Debt-to-Equity Ratio
59.58
Current Ratio
1.79
Quick Ratio
1.27

Sales & Book Value

Annual Sales
£2.73 billion
Price / Sales
1.69
Cash Flow
GBX 250.39 per share
Price / Cash Flow
8.34
Book Value
GBX 990 per share
Price / Book
2.11

Miscellaneous

Outstanding Shares
221,010,000
Free Float
N/A
Market Cap
£4.61 billion
Optionable
Not Optionable
Beta
0.43
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Mazen Samih Taleb Darwazah (Age 65)
    Exec. Vice Chairman & Pres of MENA
    Comp: $1.95M
  • Mr. Riad Mishlawi
    Chief Exec. Officer
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 51)
    Chief Financial Officer
  • Mr. Guy Featherstone
    Associate Director of Investor Relations
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 58)
    CPA, Exec. VP of Corp. Devel. and M&A
  • Mr. Hussein Omar Arkhagha
    Chief HR Officer & Company Sec.
  • Ms. Susan Ringdal
    Exec. VP of Strategic Planning & Global Affairs
  • Mr. Brian Hoffmann
    Pres of Generics
  • Mr. Samuel Park
    Global Head of Intellectual Property (IP) & Gen. Counsel for US
  • Mr. William Larkins Ph.D.
    Pres of Injectables Bus.

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HIK shares.
View HIK analyst ratings or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price forecast for 2023?

6 Wall Street analysts have issued 1-year target prices for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,740 to GBX 2,125. On average, they anticipate the company's stock price to reach GBX 1,939.17 in the next year. This suggests that the stock has a possible downside of 7.1%.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at GBX 1,552 on January 1st, 2023. Since then, HIK shares have increased by 34.5% and is now trading at GBX 2,088.
View the best growth stocks for 2023 here.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, August 3rd. Stockholders of record on Thursday, August 10th will be paid a dividend of GBX 0.25 per share on Friday, September 15th. This represents a dividend yield of 0.95%. The ex-dividend date of this dividend is Thursday, August 10th. The official announcement can be accessed at this link.
Read our dividend analysis for HIK.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 50 per share and currently has a dividend yield of 2.35%. The dividend payout ratio is 9,259.26%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 2,088.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £4.61 billion and generates £2.73 billion in revenue each year. The company earns £146 million in net income (profit) each year or GBX 0.54 on an earnings per share basis.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -